Literature DB >> 2009538

Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor.

B M Mueller1, C A Romerdahl, J M Trent, R A Reisfeld.   

Abstract

The human melanoma cell line M24met metastasizes spontaneously from s.c. tumors to multiple distant sites in mice with severe combined immunodeficiency. Metastasis to lymph nodes and lungs is found in 100% of the animals. M24met has an undifferentiated phenotype and extra copies of the short arm of chromosome 7. This cell line expresses the epidermal growth factor receptor, and 425.3, a monoclonal antibody to the epidermal growth factor receptor, binds to 291,000 receptor molecules per M24met cell with a KD of 2.3 x 10(-10) M. This antibody has no effect on the proliferation of M24met cells under tissue culture conditions and does not mediate effector cell or complement-dependent cytotoxicity of these cells in vitro. However, treatment of established s.c. M24met tumors in mice with severe combined immunodeficiency with monoclonal antibody 425.3 specifically suppresses spontaneous metastasis of these tumors. Total doses of 4, 2, and 1 mg antibody per mouse decrease the number and size of melanoma metastases and prolong the life span of treated animals. Treatment with 4 mg of the F(ab')2 fragment of monoclonal antibody 425.3 does not influence M24met melanoma metastasis, implying a significant contribution of the Fc portion to the antimetastatic effect of this antibody.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009538

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Cytokine sensitivity of metastatic human melanoma cell lines-- simultaneous inhibition of proliferation and enhancement of gelatinase activity.

Authors:  A Ladányi; J O Nagy; A Jeney; J Tímár
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 3.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

4.  Expression of a decorin-like moleculein human melanoma.

Authors:  A Ladányi; M Gallai; S Paku; J O Nagy; J Dudás; J Tímár; I Kovalszky
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

5.  Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Authors:  Tamás Garay; Eszter Molnár; Éva Juhász; Viktória László; Tamás Barbai; Judit Dobos; Karin Schelch; Christine Pirker; Michael Grusch; Walter Berger; József Tímár; Balázs Hegedűs
Journal:  Pathol Oncol Res       Date:  2015-03-09       Impact factor: 3.201

6.  Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling.

Authors:  Ase Bratland; Piet J Boender; Hanne K Høifødt; Ingrid H G Østensen; Rob Ruijtenbeek; Meng-Yu Wang; Jens P Berg; Wolfgang Lilleby; Øystein Fodstad; Anne Hansen Ree
Journal:  Clin Exp Metastasis       Date:  2009-03-18       Impact factor: 5.150

7.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

Authors:  M Naramura; S D Gillies; J Mendelsohn; R A Reisfeld; B M Mueller
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

Review 8.  Potential of the scid mouse as a host for human tumors.

Authors:  B M Mueller; R A Reisfeld
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

Review 9.  Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis.

Authors:  R S Kerbel; I Cornil; D Theodorescu
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

10.  Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo.

Authors:  Y Andersson; O Engebraaten; Ø Fodstad
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.